Skip to content

Bile Acids and Gut Microbiota as Potent Coronary Atheroma Risk Factors: a Prospective Study in Human

The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02375893
Acronym
MABAC
Enrollment
80
Registered
2015-03-03
Start date
2015-02-28
Completion date
2015-12-31
Last updated
2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Disease

Keywords

Coronary disease, Bile acids, Gut microbiota, Risk factors, Atherosclerosis

Brief summary

The purpose of this study is to describe the composition of bile acids and the gut microbiota comparing two populations: patients with coronary atheroma and the healthy subjects. Our hypothesis is based on the demonstration of the anti atherogenic and anti inflammatory effect of certain bile acids, and the role of the gut microbiota in the metabolic regulation.

Detailed description

Atherosclerosis is the main cause of cardiovascular diseases which remain the first cause of death worldwide. The prevention of risk factors can reduce the development of cardiovascular diseases. The final goal of our study is to find new protective or new risk factors that can be modulated to reduce the incidence of cardiovascular events. Gut microbiota and its main metabolite, the bile acids, are implicated in the metabolic regulation. Some bile acids, especially the secondary bile acids, transformed from the primary bile acids by the bacteria of the gut microbiota, are now demonstrated in murine experimental atherosclerosis models, to be anti inflammatory and anti atherogenic molecules. We want to compare the pool of bile acids and the composition of gut microbiota between the coronary patients and the healthy subjects to identify the potential protective or deleterious bacteria / bile acids. All patients admitted for a scheduled coronary angiogram will be included, then divided into two groups: coronary or healthy, based on the presence or the absence of atheroma during the coronary angiogram. Feces and blood samples, and clinical and biological data, will be collected during the patient's hospitalisation. No additional exam will be performed. The blood sample will be collected during the coronary angiogram or during a routine blood test.

Interventions

OTHERNo intervention

Collecting blood and feces samples

OTHERHealthy subject

Collecting blood and feces samples

Sponsors

URC-CIC Paris Descartes Necker Cochin
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

\- All patients admitted for a coronary angiogram

Exclusion criteria

* Statins, hypolipemic drugs, corticoids, anti HIV drugs * Antibiotics adminisitration in the last 3 months * Past of cholecystectomy * Hepatic disorders * Acute coronary syndrome * No agreement, Insufficiency in comprehension * Non fasting for at least 8 hours

Design outcomes

Primary

MeasureTime frameDescription
Gut microbiota composition in coronary patients versus healthy subject8 monthsObservational only

Secondary

MeasureTime frameDescription
Bile acids composition in coronary patients versus healthy subjects, in feces and blood samples8 monthsObservational

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026